FDA approves expanded age range for the pneumonia vaccine. Read More »

SPIRE-HR and SPIRE-FH lipid-lowering studies meet primary endpoints. Read More »

Nielsen recognizes brands that sustain more than $50 million in first year of sales and maintain 90 percent of the sales level in second year. Read More »

Pfizer Inc. recently announced its completed acquisition of Anacor Pharmaceuticals, Inc., giving each outstanding Anacor common stock share the opportunity to gain $99.25 net in cash as part of the acquisition. Read More »

Britol-Myers Squibb recently appointed Murdo Gordon its new EVP and chief commercial officer. Read More »

The Pfizer Get Old community and Idiegogo's entrepreneurs invited to submit products or services that support healthy aging. Read More »

New data has become available from a CheckMate -205 multi-cohort Phase II trial for Bristol-Myers Squibb’s Opdivo this past week. Read More »

Biotie Therapies Corp. announced on Monday that it has officially delisted its American depository shares (ADS) from the NASDAQ Global Select Market (NASDAQ US). Read More »

Pfizer recently announced that several studies and analyses for its tofacitinib citrate (XELJANZ) treatment for rheumatoid arthritis (RA) will be featured at the European League Against Rheumatism Annual Congress (EULAR 2016). Read More »

The U.S. Food and Drug Administration’s (FDA) Advisory Committees has recommended extended-release capsules for ALO-02 from Pfizer. Read More »

Pfizer announced last week that Jim Furyk has joined the company in advocating awareness for older individuals at risk for infectious diseases, including pneumococcal pneumonia. Read More »

The Business Council of New York State is not supporting legislation that seeks to amend the pharmaceutical law governing the purchase of prescription drugs. Read More »

New safety and efficiency data included on labels after EAGLES clinical trial. Read More »

Cigna Corp. may receive additional price discounts from pharmaceutical companies should new cholesterol medications prove less effective than expected — a move marks a crucial step in a broader initiative to link the cost of medications to their efficacy. Read More »

Fourteen presentations will present results of avelumab treatments for seven different cancer types. Read More »

Pfizer will showcase its growing portfolio of innovative treatments for a variety of cancers. Read More »

Communication key to developing treatment goals and disease management plan. Read More »

Pfizer will acquire crisaborole, a treatment for eczema, in the deal. Read More »

The clinical trial will test bococizumab versus a placebo in reducing the risk of a major cardiovascular event. Read More »

CHANTIX/CHAMPIX compared to bupropion, nicotine patch and placebo; study finds significantly higher abstention rates. Read More »